HR Alert: Employers Can Offer Standalone Fertility Plans With $120K Lifetime Cap

Talent acquisition and retention teams should watch this rule closely: the ability to offer a generous, standalone fertility benefit could differentiate employers in competitive labor markets. However, the tax division between medical infertility and other paths to parenthood could spark internal equity complaints, requiring careful communication and benefit design.

In May 2026, a cross-agency proposal from the Departments of Treasury, Labor, and Health and Human Services introduced a new regulatory concept: excepted fertility benefits. If finalized, the rules would for the first time permit employers to offer fertility benefits as standalone, voluntary plans—exempt from many of the complex mandates that govern traditional group health plans under the Affordable Care Act and ERISA. The move stems from President Trump’s February 2025 Executive Order 14216, which called for expanding access to in-vitro fertilization (IVF) and related services. The core innovation is that participants could receive up to $120,000 in lifetime fertility benefits (indexed to medical inflation after 2027) without being enrolled in the employer’s major medical plan. Employers could charge premiums and impose cost-sharing, and participation would be entirely optional.

“

The core innovation is that participants could receive up to $120,000 in lifetime fertility benefits (indexed to medical inflation after 2027) without being enrolled in the employer’s major medical plan.

This framework borrows from existing excepted benefits categories like standalone dental and vision plans, which have long been used to provide focused coverage outside the ACA’s essential health benefits and rating rules. By slotting fertility benefits into that same regulatory safe harbor, the proposal aims to reduce the administrative and financial burden on employers who want to offer fertility coverage but balk at overhauling their primary health plans. The $120,000 cap—substantial enough to cover multiple IVF cycles for many—signals an intent to make meaningful coverage available. However, the proposal explicitly does not alter the tax treatment of such benefits. Under Internal Revenue Code Sections 105, 106, and 213(d), only those with a diagnosis of medical infertility can receive employer-sponsored fertility benefits on a tax-free basis. Same-sex couples, single individuals, and others who pursue parenthood through assisted reproduction without a medical infertility diagnosis would face taxable benefits—creating a two-tier system that could undermine the expansion goal.

The rulemaking process is at a critical juncture, with public comments due July 13, 2026. If finalized, the rules would take effect for plan years starting on or after January 1, 2027. The short timeline reflects the administration’s urgency, but also leaves little room for thorough stakeholder engagement. Employers, insurers, fertility clinic networks, and employee advocacy groups will need to quickly assess the operational and legal implications. The comment period will be a key battleground over the scope of medical infertility, the indexing formula, and whether additional protections are needed to avoid discrimination claims.

From a market perspective, the proposed rules could significantly boost the fertility services sector, which has seen sustained demand growth. Fertility benefit managers like Progyny and Carrot saw valuations soar on the promise of employer-sponsored coverage. A new regulatory pathway for standalone plans could accelerate adoption by midsize employers that previously found full integration prohibitive. However, the tax uncertainty may chill participation by employers concerned about equitable treatment of their workforces. If only a subset of employees can receive tax-free benefits, the resulting disparity could spark internal morale issues and even legal challenges under state anti-discrimination laws or the Equal Protection Clause.